Get the Stockscreener App
22.97
3.53%
-0.84
Pre-market:
23.00
0.03
+0.13%
Eton Pharmaceuticals Inc stock is traded at $22.97, with a volume of 583.41K.
It is down -3.53% in the last 24 hours and up +25.66% over the past month.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
See More
Previous Close:
$23.81
Open:
$23.895
24h Volume:
583.41K
Relative Volume:
2.07
Market Cap:
$626.72M
Revenue:
$79.95M
Net Income/Loss:
$-4.60M
P/E Ratio:
-128.54
EPS:
-0.1787
Net Cash Flow:
$10.19M
1W Performance:
+21.41%
1M Performance:
+25.66%
6M Performance:
+15.25%
1Y Performance:
+55.31%
1-Day Range:
$22.85
$23.96
1-Week Range:
$18.82
$23.96
52-Week Range:
$11.09
$23.96
Eton Pharmaceuticals Inc Stock (ETON) Company Profile
Name
Eton Pharmaceuticals Inc
Sector
Phone
(847) 787-7361
Address
21925 W. FIELD PARKWAY, DEER PARK, IL
Compare ETON vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ETON
Eton Pharmaceuticals Inc
|
22.97 | 626.72M | 79.95M | -4.60M | 10.19M | -0.1787 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-25 | Reiterated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | B. Riley Securities | Buy |
| Jan-06-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-04-24 | Resumed | H.C. Wainwright | Buy |
| May-06-24 | Initiated | Craig Hallum | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Jan-04-21 | Reiterated | H.C. Wainwright | Buy |
| Sep-20-19 | Initiated | B. Riley FBR | Buy |
| Jun-10-19 | Initiated | H.C. Wainwright | Buy |
View All
Eton Pharmaceuticals Inc Stock (ETON) Latest News
Eton Pharmaceuticals (ETON) Jumps 6.7%: Does the Stock Have More Room to Grow? - Bitget
Eton Pharmaceuticals (ETON) Soars 6.7%: Is Further Upside Left in the Stock? - Yahoo Finance
Does Eton Pharmaceuticals (ETON) have the potential to rally 49.25% as Wall Street analysts expect? - MSN
Eton Pharmaceuticals (NASDAQ:ETON) Sets New 52-Week High After Analyst Upgrade - MarketBeat
Recent Price Trend in Eton Pharmaceuticals (ETON) is Your Friend, Here's Why - Yahoo Finance
H.C. Wainwright raises Eton Pharmaceuticals price target on growth goals By Investing.com - Investing.com Canada
Dow Update: Is Eton Pharmaceuticals Inc still a buy after recent gainsMarket Performance Report & Consistent Income Trade Recommendations - baoquankhu1.vn
Zacks Research Upgrades Eton Pharmaceuticals (NASDAQ:ETON) to Strong-Buy - MarketBeat
Eton Pharmaceuticals (NASDAQ:ETON) Rating Increased to Buy at Wall Street Zen - MarketBeat
Eton Pharmaceuticals Maps Aggressive Rare-Disease Growth Path - TipRanks
Eton Pharmaceuticals receives Investment Bank Analyst Rating Update By Investing.com - Investing.com Canada
Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
B. Riley Financial Forecasts Strong Price Appreciation for Eton Pharmaceuticals (NASDAQ:ETON) Stock - MarketBeat
Craig Hallum Forecasts Strong Price Appreciation for Eton Pharmaceuticals (NASDAQ:ETON) Stock - MarketBeat
Eton Pharmaceuticals (NASDAQ:ETON) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Does Eton Pharmaceuticals (ETON) Have the Potential to Rally 49.25% as Wall Street Analysts Expect? - sharewise.com
Does Eton Pharmaceuticals (ETON) Have a Chance to Surge 49.25% According to Wall Street Analysts' Predictions? - Bitget
B.Riley raises Eton Pharmaceuticals stock price target on strong Q4 results - Investing.com Canada
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2025 Earnings Call Transcript - Insider Monkey
Eton Pharma 2025 Financial Results & 2026 Outlook | Product Launches Drive GrowthNews and Statistics - IndexBox
Portfolio Update: Can Eton Pharmaceuticals Inc. lead its sector in growth2026 Geopolitical Influence & Consistent Income Trade Ideas - baoquankhu1.vn
Eton Pharmaceuticals 2023 Financial Results: Revenue, Net Income, and Key Financial Highlights - Minichart
Eton Pharmaceuticals (ETON) Turns Q4 Profit As Trailing Losses Test Bullish Growth Narrative - Sahm
Eton Pharmaceuticals Inc (ETON) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
Eton Pharmaceuticals 2025 Annual Report: Rare Disease Drug Portfolio, Regulatory Pathways, and Risk Factors Overview - Minichart
Is Eton Pharmaceuticals Inc a cyclical or defensive stock2026 Key Lessons & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Eton Pharmaceuticals, Inc. (ETON) Q4 earnings lag estimates - MSN
Eton Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Eton Pharmaceuticals (NASDAQ:ETON) Releases Quarterly Earnings Results, Misses Expectations By $0.07 EPS - MarketBeat
Eton Pharmaceuticals, Inc. (ETON) Q4 Results Fall Short of Projections - Bitget
ETON: 2025 revenue more than doubled year-over-year, with strong margin gains and robust growth outlook - TradingView
Eton Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance
Eton Pharma (ETON) Earnings Call Transcript - The Globe and Mail
Earnings call transcript: Eton Pharmaceuticals Q4 2025 beats EPS, stock rises - Investing.com
Eton Pharmaceuticals earnings beat by $0.01, revenue fell short of estimates - Investing.com Canada
Eton Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Eton Pharmaceuticals, Inc. (ETON) Q4 Earnings Lag Estimates - Yahoo Finance
ETON PHARMACEUTICALS ($ETON) Releases Q4 2025 Earnings - Quiver Quantitative
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
ETON: 2025 revenues doubled to $80M, but higher costs led to a net loss; growth expected ahead - TradingView
Eton Pharmaceuticals (NASDAQ: ETON) outlines rare-disease drugs, pipeline and IRA pricing risks - Stock Titan
Eton Pharmaceuticals (NASDAQ: ETON) posts strong 2025 growth and bullish 2026 outlook - Stock Titan
BRIEF-Eton Pharmaceuticals Q4 Net Income USD 1.483 Million - TradingView
Eton Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
Eton Pharmaceuticals (NASDAQ:ETON) Shares Up 5.8%Time to Buy? - MarketBeat
Eton Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Analysts’ Top Healthcare Picks: Eton Pharmaceuticals (ETON), Zenas BioPharma, Inc. (ZBIO) - The Globe and Mail
Aug Outlook: What drives Eton Pharmaceuticals Incs stock priceDividend Hike & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Divisadero Street Capital Management LP Trims Stock Holdings in Eton Pharmaceuticals, Inc. $ETON - MarketBeat
Cannell Capital LLC Buys 67,230 Shares of Eton Pharmaceuticals, Inc. $ETON - MarketBeat
Why (ETON) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Eton Pharmaceuticals Inc Stock (ETON) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
1.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):